搜尋
Black Diamond Therapeutics Inc
BDTX添加自選
1.690USD
-0.025-1.46%
收盤 07-31 16:00（美東）報價延遲15分鐘
96.84M總市值
虧損本益比TTM
關於 Black Diamond Therapeutics Inc 公司
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc簡介
公司代碼BDTX
公司名稱Black Diamond Therapeutics Inc
上市日期Jan 30, 2020
CEOVelleca (Mark A)
員工數量24
證券類型Ordinary Share
年結日Jan 30
公司地址245 First Street, 18Th Floor
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02142
電話16174175868
網址https://www.blackdiamondtherapeutics.com/
公司代碼BDTX
上市日期Jan 30, 2020
CEOVelleca (Mark A)
Black Diamond Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
常見問題
Black Diamond Therapeutics Inc的前五大股東是誰？
Black Diamond Therapeutics Inc的前五大股東如下：Dr. Ali Behbahani, M.D.
有多少機構持有Black Diamond Therapeutics Inc(BDTX)的股份？
截至2026Q1，共有265家機構持有Black Diamond Therapeutics Inc的股份，合計持有的股份價值約為45.02M，占公司總股份的78.72% 。與2025Q4相比，機構持股有所增加，增幅為-14972289.00。